Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging

Radiology

Volumn 207, Issue 3, 1998, Pages 791-797

  Barentsz, Jelle O ^a   Berger Hartog, Olette ^a   Witjes, J Alfred ^a   Van Der Kaa, Christina Hulsbergen ^a   Oosterhof, Gosse O N ^a   Vanderlaak, Jeroen A W M ^a   Kondacki, Herman ^a   Ruijs, Sjef H J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder neoplasms, 83.32; Bladder neoplasms, MR, 83.121416, 83.12143; Bladder neoplasms, therapy, 83.1299; Magnetic resonance (MR), treatment planning, 83.121416, 83.12143

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TUMOR VOLUME;

EID: 0031841438     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.207.3.9609906     Document Type: Article

References (22)

1. Jewett HJ. Cancer of the bladder. Cancer 1973; 32:1072-1076.
2. Perry JJ, Muss HB. Management of disseminated disease in the patient with bladder cancer. Urol Clin North Am 1994; 21:661-672.
3. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989; 64:2448-2252.
4. Tannock I, Gospodarowicz M, Conolly J, et al. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989; 142:289-294.
5. Igawa M, Ohkuchi T, Ueki T, et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990; 144:662-666.
6. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050-1054.
7. Boutan-Laroze A, Mohjoubi M, Droz JP, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder: the French Federation of Cancer Centers experience. Eur J Cancer Clin Oncol 1991; 27:1690-1696.
8. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative study group study. J Clin Oncol 1992; 10:1066-1071.
9. Barentsz JO, Ruijs JHJ, Strijk SP. The role of MR Imaging in carcinoma of the urinary bladder: a review. AJR 1993; 160:937-947.
10. Boetes CB, Barentsz JO, Mus RDM, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced turbo-FLASH subtraction technique. Radiology 1994; 193:777-783.
11. Verstraete KL, De Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging - parametric "first-pass" images depict tissue vascularization and perfusion. Radiology 1994; 192:835-843.
12. Jager GJ, Ruijter ETG, van der Kaa CA, et al. Dynamic turbo-FLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathology. Radiology 1997; 203:645-652.
13. Barentsz JO, Jager GJ, van Vierzen PBJ, et al. Staging urinary bladder cancer after transurethral biopsy: the value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201:185-193.
14. Vaupel PW. Blood flow, oxygenation, tissue pH distribution and bioenergetic status of tumors. Berlin, Germany: Hellmich KG, 1994.
15. Weidner N. Intratumor microvessel density as a prognostic factor (comment). Am J Pathol 1995; 147:9-19.
16. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GNA, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74:762-766.
17. Frouge C, Guinebretiere J-M, Contesso G, Di Paola R, Blery M. Correlation between contrast enhancement in MR imaging of the breast and tumor angiogenesis. Invest Radiol 1994; 29:1043-1049.
18. Lang P, Vahlensieck M, Matay KK, et al. Monitoring neovascularity as an indication of response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Med Pediatr Oncol 1996; 26:329-333.
19. Vandijke C, Brasch R, Roberts T, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterization of tumor microvasculature and histologic capillary density. Radiology 1996; 198:813-818.
20. Passe TJ, Bluemke DA, Siegelman SS. Tumor angiogenesis: tutorial on implications for imaging. Radiology 1997; 203:593-600.
21. Witjes JA, Wiltink M, de Mulder P, Oosterhof G. Toxicity and results of MVAC chemotherapy in advanced transitional cell carcinoma. Eur Urol (in press).
22. Degani H, Furman E, Field S. Magnetic resonance imaging and spectroscopy of MCF17 human breast cancer: pathophysiology and monitoring of treatment. Clin Chim Acta 1994; 228:19-33.